Altered fibrinolytic activities in gastric cancer and uremic patients after intervention.
BACKGROUND
Although thromboembolism is the most recognized cause of death in cancer and uremic patients following tumorectomy or hemodialysis, respectively, little data exist concerning its etiologies and treatments in post-intervention settings. In this study, we determined the post-intervention fibrinolytic activities to exploit their implications in gastric cancer and uremic patients.


METHODS
A small-scale case-control study with totally 56 cases aimed to compare the difference of the post-intervention fibrinolytic activities of two hypercoagulable groups of gastric cancer and uremic patients versus healthy controls was conducted. In-house functional assays for plasma plasminogen (Pg) and plasminogen activators (PA) activities were employed.


RESULTS
As compared to the control, both variable-stratified patient groups disclosed reduced Pg activities, synonyms at the "hypofibrinolytic" state, suggesting that the alleged post-intervention hypercoagulability of the two patient groups could be rationalized by the hypofibrinolysis mechanism. On the other hand, cancer patients showed elevated PA activity, concomitantly implicating that there was associated fibrinolytic consumption. Moreover, the altered PA activity could be ascribed to tumor metastasis according to literature review.


CONCLUSIONS
Our data suggested that the PA/Pg fibrinolytic activities were altered in gastric cancer and uremic patients post-interventionally. Measurement of the post-intervention fibrinolytic activities could be useful in projection of some potential risks.
Chen
J-S
JS
Divisions of Nephrology, Tri-Service General Hospital, Taipei, Taiwan.
Chan
D-C
DC
Chung
M-J
MJ
Chang
L-C
LC
Yang
V C
VC
D005260:Female; D005342:Fibrinolysis / Q000502:physiology*; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D010960:Plasminogen Activators / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood* / Q000628:therapy; D013927:Thrombosis / Q000097:blood / Q000209:etiology*; D014511:Uremia / Q000097:blood* / Q000628:therapy
D010958:Plasminogen; D010960:Plasminogen Activators